PHASE III STUDY

• Randomised, active controlled, open label, parallel treatment group, multicentre phase III study

• One month baseline period

• Test and control patients (2:1 ratio) studied for 6 months

• Followed by a one month follow up period or extension study (6 months)

  
  

Diapositiva anterior

Diapositiva siguiente

Ir a la primera diapositiva

Ver versión gráfica